Legend Capital has made the first close of the third USD-denominated China healthcare fund at $177 million. In a separate development, Ustar Biotechnologies (Hangzhou) has raised over 300 million yuan ($47 million) in its Series E+ round of financing.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
